Overview

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Status:
Terminated

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).

Phase:

Phase 3

Details

Lead Sponsor:

Abbott

Collaborators:

Harvard University
Massachusetts General Hospital

Treatments:

Ergocalciferols